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The structures of some bisphosphonates (clodronate, etidronate, pamidronate, alendronate, risedronate, zoledronate, min-
odronate) were obtained and analyzed, and their adsorption energies onto hydroxyapatite (001) surface were compared to find out
ranking order of binding affinity, which shows that the adsorption energy is the largest for pamidronate, followed by alendronate,
zoledronate, clodronate, ibandronate, the lowest for minodronate and etidronate.
1 Introduction
Bisphosphonates (BPs) are now widely used for the treatment
of metabolic bone diseases including osteoporosis, Paget’s
disease and bone metastases11,15,33,36,37. In addition, BPs are
also useful as novel ligands for well-defined radioactive metal
complexes that can be used both for bone scanning imaging
and for therapeutic applications48. BPs have high affinity for
calcium ions and therefore bind strongly to the principal bone
mineral, hydroxyapatite (HAP), where they are internalized by
bone-resorbing osteoclasts and inhibit their function16,19,23,24.
BPs are metabolically stable analogues of inorganic py-
rophosphate (PPi), a naturally occuring modulator of calcifica-
tion. Stability is confered by a carbon atom replacing the oxy-
gen atom which connects two phosphonates. BPs of medical
interest all have two phosphonate groups sharing a common
carbon atom between them(Figure 1). BPs have chemical and
Fig. 1 General Structure of BPs
physical properties similar to pyrophosphate20,34 but, due to
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their P-C-P backbone, they are considerably more resistant to
heat and enzymatic hydrolysis. Both phosphonate groups are
required, as modifications to one or both reduce the affinity14,
as well as reduce biochemical potency13,45. R1 substituents
such as hydroxyl (OH) and amino (NH2) can enhance chem-
ical adsorption with their additional abilities to co-ordinate to
calcium4,10. Varying R2 substituent(Figure 2), the antiresorp-
tive potency changes in several orders of magnitude14. Bis-
phosphonates with R2 chain containing a basic primary nitro-
gen atom in an alkyl chain (e.g., pamidronate, alendronate,
and neridronate) are more potent antiresorptive than not con-
taining nitrogen atom (e.g., clodronate and etidronate). More
highly substitution of nitrogen atom in an alkyl chain (e.g., ol-
padronate and ibandronate) can display further increase in an
antiresorptive potency42. The most potent antiresorptive bis-
phosphonates include those containing nitrogen atom within
an heterocyclic ring (e.g., risedronate, zoledronate, and min-
odronate)27,28. The overall pharmachological effects of BPs
are mainly related to binding affinity for bone mineral (HAP)
and inhibitory effects on osteoclasts11.
Strong binding affinity of BPs on bone mineral can influ-
ence on some important biological properties of these drugs,
including uptake and retention on bone, diffusion within bone,
release from bone, and recycling back onto bone surface9,35.
The mineral binding affinity may also affect the appropriate
dosing interval and the persistence of effect after discontinua-
tion of medication7,17. Therefore, binding affinity of BPs on
bone mineral may play an important role on the pharmacolog-
ical effects of these drugs.
There are some reports on experiments of measuring and
comparing binding affinities of BPs on bone. By using a con-
stant composition potentiostatic method, Nancollas et al stud-
ied the kinetic mineral binding affinities of bisphosphonates
to identify zoledronate and alendronate as the higher affinity
agents followed by ibandronate and risedronate18. Lawson
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Fig. 2 Classification of BPs
and co-workers have developed FPLC (fast performance liq-
uid chromatography) utilizing crystaline HAP, which showed
that zoledronate had a longer retention time compared to rise-
dronate, indicating a stronger binding affinity for HAP30.
Leu and co-workers studied bisphosphonate adsorption on
human bone by competitive binding assays of radio-labeled
bisphosphonates, which showed that most tested BPs, in-
cluding etidronate, ibandronate, pamidronate, alendronate,
risedronate, and zoledronate had comparable affinities, but
tiludronate and especially clodronate displayed significantly
weaker affinity for bone6. Jahnke et al, using NMR tech-
niques, provided even more accurate comparison of thermo-
dynamic binding affinities46 that parallels the Leu rankings6.
Mukherjee et al studied the thermodynamic properties of bis-
phosphonates binding to human bone in more detail using 31P
NMR to obtain another set of affinity rankings40,41, which
showed that similar to the results of Nancollas et al18 rise-
dronate has lower affinity, while zoledronate and alendronate
have the highest affinity. In recent studies, mass spectrometry
(MS) has been applied for specific identification and quan-
tification of BPs, which has enabled the efficient separation
and quantification of BPs with their binding affinities49. The
combination of FPLC with MS provides an accurate, precise,
and robust method for quantitative analysis49. Although there
are some differences in ranking orders of BPs binding affinity
among various adsorption assays, in general, amino-alkyl BPs
including pamidronate, alendronate, and neridronate have the
highest affinities, while clodronate has the lowest affinity, and
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risedronate displays intermediate affinity (Table 1).
Table 1 Comparison of rank orders of HAP binding affinities of BPs
among different adsorption assays
Ranking order Expa Expb Expc Expd Expe
1 ZOL ALN PAM PAM PAM
2 PAM ZOL ALN ALN ALN
3 ALN PAM ZOL ETD NER
4 IBN RIS RIS NER ETD
5 RIS ETD IBN ZOL ZOL
6 ETD IBN RIS IBN
7 CLO TIL IBN MIN
8 CLO MIN RIS
9 CLO CLO
a Constant composition kinetic studies of HAP crystal growth
(Nancollas18)
b Competitive binding assay of radio-labeled BPs (Leu6)
c NMR-based competitive binding assay (Jahnke46, Mukherjee 40,41)
d Fluorescence competitive binding assay (Duan49)
e HAP FPLC (Duan 49)
Structure-activity data in these studies show that small dif-
ferences in BP structure lead to substantial changes in the three
dimensional (3-D) shape and atomic orientation, resulting in
significant changes in bone affinity.
Therefore, computational modeling and simulations are
widely used to establish accurate and precise relationship be-
tween structure and bone affinity of BPs based on molec-
ular and atomic level for development of further promising
BPs8,12,31. Modeling studies by Lawson et al31 indicated that
N atoms in the BP side chains can coordinate with OH groups
in HAP with bonding efficiencies related to their overall bind-
ing affinity. Comparative modeling of BPs by Ebetino et al12
demonstrated that N atoms of BPs can form a N-H-O hydro-
gen bond to the labile OH and a bifurcated interaction at the
P-O oxygen atoms of HAP (001) surface. Duarte et al8 per-
formed molecular mechanics simulations for molecular struc-
tures of 18 novel hydroxyl- and amino-BPs to examine the in-
teraction between BPs and HAP and to extract relating struc-
tural characteristics of BPs and their affinities for the mineral,
which are in agreement with in vitro and in vivo studies for
some of the studied BPs. These modeling and simulations are
based on molecular mechanics with well-defined forcefields,
that is not good for physico-chemical process such as adsorp-
tion of BPs on HAP surface accompanied with charge move-
ment, in which density functional theory (DFT) provides rea-
sonable results.
In recent years, DFT method are widely used for struc-
tural characteristics of BPs and HAP and interaction between
them3,38,47. The surface energetics of HAP crystalline sur-
faces using ab initio density functional theory (DFT) calcu-
lations within the generalized gradient approximation (GGA)
for the exchange-correlation functional has been studied by
Zhu and Wu47, testing the effects of slab thickness, vacuum
width between slabs, and surface relaxation on surface en-
ergy. Barrios3 has investigated the interaction between colla-
gen protein and HAP surface by using a combination of com-
putational techniques, DFT and classical MD methods. More
recently, the adsorption process of zoledronate on HAP (001)
surface were examined in detail, which showed that the signif-
icant charge movement between BPs and HAP (001) surface
occurs and the strong binding affinity of zoledronate with HAP
is due to structural similarity38.
In this paper, using ab initio DFT method, the molecu-
lar structures of 8 BPs (clodronate, etidronate, pamidronate,
alendronate, ibandronate, risedronate, zoledronate, and min-
odronate) are obtained, and the binding affinity is evaluated
via their adsorption energies onto HAP (001) surface.
2 Computational Method
DFT calculations are performed together with molecular me-
chanics (MM) calculations. MM is less expensive computa-
tionally, but not more accurate and precise than DFT. There-
fore, MM is needed to find rough and globally-optimised
structures using simulated annealing39, in which the temper-
ature is increased from 300K to 5000K, and decreased back
to 300K in 100,000 steps. For MM calculations, we have
used GULP (General Utility Lattice Program) code25 with
Dreiding forcefield43 and QEq atomic charges2. Globally-
optimised rough structure obtained in MM calculation goes
for more accurate and precise structural relaxation in DFT cal-
culation.
For DFT calculations, we have employed SIESTA
code44 which solves numerically Kohn-Sham equation within
DFT22,29 using a localized numerical basis set, namely pseudo
atomic orbitals, and pseudopotentials for describing the inter-
action between ionic core (nucleus plus core electrons) and
valence electrons. The BLYP GGA functional (the Becke
exchange functional1 in conjunction with the Lee-Yang-Parr
correlation functional5) is used for exchange-correlation in-
teraction between electrons. For all the atoms, Troullier-
Martins32 type norm-conserving pseudopotentials are gener-
ated within local density approximation (LDA)26, and the
DZP type (double f plus polarization) basis sets are used. The
mesh size of grid, which is controlled by energy cutoff to set
the wavelength of the shortest plane wave represented on the
grid, has taken a value of 200 Ry. Non-fixed atoms are allowed
to relax until the forces converge less than 0.02 eV/A2.
To simulate adsorption of BPs onto HAP surface, initial
configuration of BPs adsorbed onto HAP surface must be
given, from which globally-optimized configuration is ob-
tained using simulated annealing in MM and further relaxation
in DFT.
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The adsorption energy of BPs onto HAP surface is given by
Eads = Esystem− (EHAP +EBP), (1)
where EHAP is the energy of surface slab, EBP, the energy of
isolated BP molecule, and Esystem, the total energy of system
consisted of HAP surface slab and BP molecule adsorbed on
it.
3 Results and Discussion
Table 2 provides structural parameters of globally-optimized
BPs structures, in which O(H) means oxygen atom linked to
hydrogen atom, and P=O means double bond between phos-
phorous atom and oxygen atom. Bond length of C–R2 de-
pends on R1 largely and bond length of P–C and bond an-
gle of P–C–P vary significantly with R2, while other param-
eters remain almost unchanged, from which P–C–P structure
is shown to be mainly related with binding affinity. Also, pi–
bond of P=O reduces bond length compared to P–O(H).
Structural and lattice parameters of HAP crystal and sur-
face are provided in Table 3, where HAP crystal is doubled
along one axis normal to the orientation of hydroxyl group to
keep its practical isotropy (See Figure 3). For convenience, Ca
atoms on Layer 1 are presented by Ca1, and those on Layer
2 by Ca2. Comparison of structural paramters of BPs with
Fig. 3 Crystal Structure of Hydroxyapatite, a) Top View, b) Side
View.
those of HAP (Table 3) shows that P–O(H) bond lengths of
BPs (1.62∼1.64) are similar to those of HAP (1.578 for crys-
tal, 1.583 for surface).
Figure 4 presents HOMO and LUMO of BPs which shows
that HOMO is distributed around nitrogen atom for N-BPs and
nitrogen atom behaves as electron donor in adsorption process.
Table 4 provides Hirshfeld charges21 of BPs, in which
O(=P) means oxygen atom double-bonding to phorous atom,
and O(H) means oxygen atom linked to hydrogen atom. As
Table 3 Lattice Parameters of HAP crystal and surface
Lattice Parameters
a, b, c 18.695, 9.354, 6.956
α , β , γ 90, 90, 119.86
Structural Parameters
Crystal Surface
Average of bond lengths
P–O 1.578 1.583
Ca1–O 2.423 2.352
Ca2–O 2.553 2.434
Average of bond angles
O–P–O 109.44 109.39
O–Ca1–O 98.62 101.50
O–Ca2–O 99.40 94.01
shown in Table 4, Hirshfeld charges of phosphorous atom and
oxygen atoms double-bonding to former remain almost un-
chaged, and those of R1, R2, and carbon atom between two
phosphorous atoms change significantly.
Figure 5 shows the adsorption geometries of BPs onto HAP
(001) surface, which indicates that hydrogen bond between
OH of BPs and O of HAP plays an important role in strong
binding of BPs onto hydroxyapatite.
Table 5 shows Hirshfeld charges of HAP crystal and sur-
face (before and after BPs adsorption). As shown in Table 5,
atomic charges of surface differ remarkably from those of
crystal before adsorption, while the adsorption of BPs relaxes
atomic charges of HAP surface towards those of crystal, so
that the adsorption of BPs stabilizes HAP surface.
Table 6 shows the adsorption energies of BPs onto
HAP(001) surface, which indicates that PAM has the great-
est value, followed by ALN, ZOL, CLO, IBN, RIS, MIN, and
ETD, which parallels the ranking orders of Table 1.
Table 6 Adsorption Energies of BPs onto HAP(001) surface.
EBP (eV) EHAP (eV) EBP-HAP (eV) EAds (eV)
CLO -3997.45 -50669.94 -54669.74 -2.35
ETD -3840.24 -50669.94 -54512.35 -2.17
PAM -4313.33 -50669.94 -54986.60 -3.33
ALN -4500.17 -50669.94 -55173.33 -3.21
IBN -5436.13 -50669.94 -56108.38 -2.31
RIS -4931.92 -50669.94 -55604.11 -2.25
ZOL -4876.41 -50669.94 -55549.28 -2.92
MIN -5528.59 -50669.94 -56200.71 -2.17
4 Conclusions
In this paper, the geometries of BPs were studied to find out
that P–C–P structure is sensitive to R2 group and mainly cor-
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Table 2 Structural Parameters of BPs. P–O(H) means single bond between phorous atom and oxygen atom linked to hydrogen atom, and P=O
means double bond between phorous atom and oxygen atom.
CLO ETD PAM ALN IBN RIS ZOL MIN
Bond Length
P–O(H) 1.62 1.64 1.64 1.64 1.63 1.64 1.63 1.63
P=O 1.49 1.49 1.49 1.48 1.49 1.48 1.49 1.49
P–C 1.88 1.99 1.94 1.93 1.90 1.95 1.97 1.90
C–R1 1.78 1.40 1.40 1.41 1.41 1.39 1.40 1.41
C–R2 1.78 1.55 1.56 1.56 1.54 1.58 1.57 1.58
Bond Angle
(H)O–P–O(H) 97.0 96.9 96.4 95.4 99.2 95.1 97.3 102.1
O=P–O(H) 119.5 116.8 116.9 118.2 116.5 118.8 116.5 116.1
C–P–O(H) 105.1 110.4 109.6 106.9 106.1 107.0 110.3 105.2
C–P=O 108.9 105.8 107.0 109.9 111.3 108.5 105.7 111.0
P–C–P 102.4 93.7 94.3 98.6 96.9 101.1 90.9 94.6
P–C–R1 110.2 110.9 113.2 107.7 109.0 113.2 112.9 109.1
P–C–R2 110.1 113.8 112.8 115.7 113.0 108.6 114.9 114.7
R1–C–R2 113.4 112.8 110.2 110.6 114.6 111.4 109.9 112.8
Fig. 4 HOMO and LUMO of BPs
Table 4 Hirshfeld Charges of BPs. O(=P) means oxygen atom double-bonding to phorous atom, and O(H) means oxygen atom linked to
hydrogen atom.
CLO ETD PAM ALN IBN RIS ZOL MIN
C -0.025 0.045 0.038 0.025 0.014 0.034 0.032 0.007
P 0.490 0.498 0.494 0.494 0.500 0.496 0.500 0.501
O(=P) -0.336 -0.353 -0.355 -0.358 -0.334 -0.343 -0.342 -0.335
H 0.152 0.157 0.154 0.162 0.142 0.160 0.153 0.147
O(H) -0.221 -0.234 -0.227 -0.229 -0.222 -0.234 -0.224 -0.221
R1 0.002 -0.055 -0.041 -0.056 -0.043 -0.043 -0.053 -0.068
R2 0.003 0.027 0.021 0.026 0.022 -0.003 -0.013 0.029
related to binding affinity onto hydroxyapatite crystal. For N-
BPs, nitrogen atom is shown to behaves as donor during the
adsorption through HOMO and LUMO analysis.
Hirshfeld charge analysis shows that during the adsorption
process, charges of BPs and HAP change reamarkably, and
BPs adsorption realaxes charges of HAP surface towards those
of HAP crystal, so that it can stabilize HAP surface.
The adsorption geometries of BPs onto hydroxyapatite
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Fig. 5 Adsorption Geometries of BPs onto HAP (001) surface.
Table 5 Hirshfeld Charges of HAP crystal and surface. Ca1 means calcium atom on Layer 1, Ca2 means calcium atom on Layer 2, O1, O2
and O3 mean oxygen atoms of phosphate tetrahedron, in which O1 places on Layer 1, and O2 and O3 on Layer 2.
HAP Surface combined with BPs
Element Crystal Surface CLO ETD PAM ALN IBN RIS ZOL MIN
Ca1 0.429 0.783 0.555 0.616 0.592 0.553 0.550 0.516 0.532 0.524
Ca2 0.415 0.508 0.460 0.478 0.479 0.471 0.471 0.468 0.477 0.478
O1 -0.290 -0.377 -0.358 -0.347 -0.335 -0.340 -0.348 -0.349 -0.341 -0.351
O2 -0.283 -0.318 -0.314 -0.308 -0.310 -0.310 -0.310 -0.313 -0.304 -0.312
O3 -0.296 -0.312 -0.309 -0.290 -0.307 -0.308 -0.307 -0.307 -0.307 -0.309
P 0.533 0.481 0.494 0.501 0.502 0.502 0.498 0.499 0.503 0.497
H 0.130 0.128 0.120 0.130 0.130 0.130 0.130 0.131 0.136 0.135
O(H) -0.355 -0.356 -0.359 -0.366 -0.362 -0.359 -0.356 -0.358 -0.362 -0.358
(001) surface shows that hydrogen bond between OH of BPs
and O of HAP plays an important role in strong binding of
BPs onto hdyroxyapatite.
Comparing the adsorption energies of BPs onto hdyroxya-
patite (001) surface, obtained by first-principles calculation,
pamidronate has the greatest value, and etidronate has the low-
est value, which parellels the experimental ranking order, i.e.
adsorption energy is the main factor determining the binding
affinity of BPs onto hydroxyapatite.
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